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Abstract
Purpose There is an ever-growing body of literature examining the relationship between dietary omega-3 polyunsaturated 
fatty acids (ω3 PUFAs) and cerebral structure and function throughout life. In light of this, the use of ω3 PUFAs, namely, 
long-chain (LC) ω3 PUFAs (i.e., eicosapentaenoic acid and docosahexaenoic acid), as a therapeutic strategy to mitigate 
cognitive impairment, and progression to Alzheimer’s disease is an attractive prospect. This review aims to summarise 
evidence reported by observational studies and clinical trials that investigated the role of LC ω3 PUFAs against cognition 
impairment and future risk of Alzheimer’s disease.
Methods Studies were identified in PubMed and Scopus using the search terms “omega-3 fatty acids”, “Alzheimer’s disease” 
and “cognition”, along with common variants. Inclusion criteria included observational or randomised controlled trials 
(RCTs) with all participants aged ≥ 50 years that reported on the association between LC ω3 PUFAs and cognitive function 
or biological markers indicative of cognitive function linked to Alzheimer’s disease.
Results Evidence from 33 studies suggests that dietary and supplemental LC ω3 PUFAs have a protective effect against cog-
nitive impairment. Synaptic plasticity, neuronal membrane fluidity, neuroinflammation, and changes in expression of genes 
linked to cognitive decline have been identified as potential targets of LC ω3 PUFAs. The protective effects LC ω3 PUFAs 
on cognitive function and reduced risk of Alzheimer’s disease were supported by both observational studies and RCTs, with 
RCTs suggesting a more pronounced effect in individuals with early and mild cognitive impairment.
Conclusion The findings of this review suggest that individuals consuming higher amounts of LC ω3 PUFAs are less likely 
to develop cognitive impairment and that, as a preventative strategy against Alzheimer’s disease, it is most effective when 
dietary LC ω3 PUFAs are consumed prior to or in the early stages of cognitive decline.




Aβ  Amyloid-beta peptide
AD   Alzheimer’s disease
ADAS-cog   Alzheimer’s disease assessment scale cogni-
tive subscale
ADL  Activities of daily living
ALA  Alpha-linolenic acid
AMT  Abbreviated mental test
ApoE  Apolipoprotein E
ARA  Arachidonic acid
CDR  Clinical dementia rating
CDT  Clock-drawing test
CIBIC  Clinician’s interview-based impression of 
change
COWAT  Controlled oral word association test
COX  Cyclooxygenase
DHA  Docosahexaenoic acid
EPA  Eicosapentaenoic acid
HVLT-DR  Hopkins verbal learning test with delayed 
recall
IADL  Instrumental activities of daily living
IL-6  Interleukin-6
LA  Linoleic acid
MCI  Mild cognitive impairment
MMSE  Mini-mental state examination
PPAR  Peroxisome proliferator-activated receptor
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LC PUFAs  Long-chain polyunsaturated fatty acids
RAVLT  Rey auditory verbal learning test
RBANS  Repeatable battery for assessment of neu-
ropsychological status
sIL-1RII  Soluble interleukin-1 receptor type-II
TICS-M  Modified telephone interview for cognitive 
status
TMT  Trail making test
TNF-α  Tumour necrosis factor-alpha
WAIS-III  Wechsler adult intelligence scale third 
edition
WAIS-R  Revised wechsler Adult intelligence scale
WMS-R  Revised wechsler memory scale
ω3 PUFAs  Omega-3 polyunsaturated fatty acids
ω6 PUFAs  Omega-6 polyunsaturated fatty acids
Dementia, Alzheimer’s disease, 
and cognitive impairment
Encompassing a collection of syndromes, dementia is char-
acterised by progressive impairment of memory, language, 
behaviour and visuospatial function, leading to compro-
mised independence [1]. It is estimated to affect 50 million 
people globally [2] and is caused by a number of diseases 
that trigger irreversible damage to cells in the brain. The 
most common of these diseases is Alzheimer’s disease (AD), 
representing 60% to 80% of dementia cases [3]. No treatment 
has yet been found to prevent or cure cognitive impairment 
or its progression to dementia and AD [3].
Cognitive impairment, especially difficulty retaining new 
information, is an early marker of AD. Numerous clinical 
tests have been validated to evaluate different aspects of cog-
nition that can identify individuals at increased risk of AD 
within a few years (e.g., rate of learning over time, immedi-
ate recall, and delayed recall) [4]. In addition to memory and 
recall, episodic assessments can be used to assess specific 
neurocognitive functions: problem‐solving, planning, lan-
guage, attention, and visuospatial skills. The diagnosis of 
cognitive impairment and elevated risk of AD is defined 
by guidelines set by the National Institute on Aging and 
the Alzheimer’s Association [4]. The guidelines offer flex-
ible assessment criteria to match the assessor’s expertise 
(general practitioner vs specialist), accessibility to diagnostic 
resources (e.g., image scanning and blood biomarkers), and 
the cognitive challenges presented by the patient. In light of 
this flexibility, there is acknowledgment that the AD popula-
tion is not homogenous, but a heterogeneous population of 
subgroups defined by their cognitive abilities and diagnostic 
criteria [5]. The effect of age on cognitive impairment is 
undeniable; however, it is important to evaluate the effect 
of modifiable environmental factors, such as diet, both on 
the prevention of cognitive decline and onset of AD. Indeed, 
identifying cardinal risk factors that commonly contribute 
to early cognitive impairment and risk of AD, could help (i) 
identify individuals at high risk of cognitive impairment, 
(ii) project an individual’s progression toward AD, and (iii) 
inform strategies to delay the onset of AD.
PUFAs as mediators of cognitive impairment
There is general agreement across studies and study design, 
of an association between healthy diets, cognitive function, 
and risk of AD [6–9]. That is, prudent and ‘Mediterranean’ 
diets, characterised by greater intake of whole grains, fresh 
fruits and vegetables, fish, and polyunsaturated fatty acids, 
associate with reduced risk of cognitive impairment, com-
pared to ‘Western’ diets characterised by processed foods, 
saturated fats, refined grains, and added sugars [10]. PUFAs, 
lipidic molecules defined by the presence of more than one 
double bond in the aliphatic chain, are typically more abun-
dant in healthy ‘whole food’ diets, such as those consumed 
in prudent and ‘Mediterranean’ diets. The two main series 
of PUFAs are omega-3 (ω3): α-linolenic acid (ALA, C18:3), 
docosahexaenoic acid (DHA, C22:6) and eicosapentaenoic 
acid (EPA, C20:5); and omega-6 (ω6): linoleic acid (LA, 
C18:2) and arachidonic acid (ARA, C20:4) [11].
Precursor ω6 and ω3 PUFAs, LA and ALA, are essen-
tial fatty acids determined by diet as they cannot be endog-
enously synthesised by humans [12], while long-chain (LC) 
PUFAs (e.g., EPA, DHA, and ARA) may be either endog-
enously synthesised from their precursor ω3 or ω6 PUFA or 
consumed directly through diet or supplementation.
ALA, found in high concentrations in chia seeds, wal-
nuts, and oils of flaxseed, canola and soybean [13], can be 
synthesised by enzymatic desaturation and elongation to 
supply the body with EPA and DHA [14]. Delta-6 desatu-
rase, the enzyme required in the first rate-limiting stage of 
ALA conversion [11], is also implicated in the metabolism 
of LA, meaning that both PUFAs compete for desaturation 
[13]. The rate of ALA conversion is, therefore, generally 
low at less than 5% [15]. Food sources of EPA and DHA 
notably consist of fish and seafood products, including fish 
oils [16]. Mean intakes of EPA and DHA through food in 
the UK have been estimated at 244 mg/day [17], substan-
tially lower than the recommended 450 mg/day as stipu-
lated by the Scientific Advisory Committee on Nutrition 
[18]. However, PUFA intake is perhaps best predicted by 
the ω6:ω3 ratio present in the diet, rather than the intake 
of a single PUFA. While ratios between 1:1 and 5:1 have 
demonstrated positive effects in ameliorating general disease 
burden [19], the modern Western diet, characterised by a 
high consumption of meat, vegetable oils, and processed 
foods, is often reported to have an ω6:ω3 in excess of 15:1 
[20]. The chronic low-grade inflammation induced by this 
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aspect of diet may have consequences for neuronal health, 
generating an environment that impairs cognitive function 
and fosters AD pathology [21]. Structurally, ω3 and ω6 LC 
PUFAs comprise around 30–35% of fatty acids in the brain 
[11] and have been shown in pre-clinical and human stud-
ies to exert effects on metabolic processes involved in brain 
development and function throughout the life course [11, 22, 
23] through modulation of membrane fluidity, gene expres-
sion, and inflammation.
Membrane fluidity
The fatty acid composition of cell membranes affects the 
membrane fluidity index by influencing membrane packing 
[11]. The abundance of LC PUFAs within the phospholipid 
fractions of the brain, predominantly DHA and ARA [14], 
increases the fluidity of neuronal membranes [12], which in 
turn modulates the function of transmembrane and periph-
eral proteins, such as receptors, enzymes and ion chan-
nels involved in vital cellular processes [11]. Following a 
decrease in absorption across the blood–brain barrier and 
changes to fatty acid metabolism, the aging brain sees a 
decrease in membrane LC PUFA concentration [12] and a 
corresponding decline in membrane fluidity—an observation 
documented in patients with clinically diagnosed cognitive 
impairment and AD [24, 25]. Interestingly, aged-related 
membrane rigidity has been reversed in the hippocampus of 
pre-clinical AD models through a DHA-enriched diet [26] 
but its effect on cognitive function in individuals already 
diagnosed with AD is inconsistent [27, 28].
Gene expression
LC PUFAs are implicated in the expression of several genes 
[29]. Targets for modulation are primarily from the nuclear 
receptor superfamily, namely, the retinoid X receptor, retinoic 
acid receptor and peroxisome proliferator-activated receptor 
(PPAR) [22]. They function as ligand-activated transcription 
factors in retinoid signalling [29], which are associated with 
synaptic plasticity, subsequent memory and learning ability 
[22] and, therefore, AD disease pathologies [30]. Interestingly, 
LC ω3 PUFAs show a greater potency in modifying nuclear 
receptor gene expression compared to LC ω6 PUFAs [31]. 
PPAR can bind to multiple fatty acids and their derivatives; 
however, PUFAs, in particular EPA, show superior binding 
affinity compared to ω6 PUFAs and saturated fatty acids [32]. 
Furthermore, increased ω3 intake may increase transthyretin 
[29], a thyroid transport protein that acts as a scavenger of 
β-amyloid (Aβ) protein fragments [14]. The aggregation and 
deposition of Aβ42 fragments as neuropathological plaques is 
considered a primary hallmark of AD [33]. A human model of 
AD has shown that over-expression of transthyretin supresses 
Aβ plaque formation, putatively through sequestration [34], 
while pre-clinical AD models suggest a causal pathway con-
necting decreased dietary ω6:ω3 ratios with increased PPAR 
signalling and improved cognitive measures [35, 36]. Collec-
tively, this positions modification of dietary LC PUFAs as a 
viable approach to improve cognitive function in AD; however, 
heterogeneity of effect sizes in human trials [37] challenges the 
generalisability of results.
Inflammation
Eicosanoids are a group of inflammatory mediators that 
include prostaglandins, thromboxanes and leukotrienes [38, 
39]. PUFAs act as precursors to the synthesis of eicosanoids 
through metabolism by cyclooxygenase (COX) and 5-lipox-
ygenase (5-LOX) enzymes [22]. ARA, a 20-carbon LC ω6 
PUFA, is in plentiful supply in neural cell membranes, making 
it the primary substrate for the majority of eicosanoid pro-
duction [38]. ARA-derived eicosanoids, which include the 
2-series of prostaglandins and thromboxanes, as well as the 
4-series of leukotrienes [22], potentiate autocrine and parac-
rine inflammation [40], with in vitro evidence suggesting they 
induce Aβ plaque formation [31]. Conversely, EPA, a 20-car-
bon LC ω3 PUFA, competes with ARA for COX and 5-LOX 
enzymes [41], thereby lessening ARA metabolism and levels 
of ARA-derived eicosanoids [38, 42]. In addition, EPA is a 
precursor for lesser pro-inflammatory eicosanoids, namely, the 
3-series of prostaglandins and thromboxanes, and the 5-series 
of leukotrienes [22, 43], and (along with DHA) anti-inflamma-
tory resolvins and neuroprotectins [38]. Of particular interest is 
neuroprotectin D1, which can inhibit COX2 expression, reduce 
ARA metabolism [44], and modulate Bcl-2 expression towards 
an anti-apoptotic state; thereby, ameliorating the deleterious 
effects of inflammation [45].
In summary, evidence from molecular, epidemiological, 
and preclinical and human studies elucidates dietary LC ω3 
PUFAs as mediators of cognitive decline and risk of AD; 
however, a summary of current literature is required to cri-
tique and evaluate the strength of existing evidence linking 
dietary LC ω3 PUFAs with cognitive decline and explain the 
heterogeneity observed in study results. By understanding 
the primary mechanisms that contribute to the development 
and progression of cognitive decline and AD, we are well 
positioned to offer an evaluation of this evidence. In doing 
so, we aim to determine the role of dietary and supplemented 
LC ω3 PUFAs as moderators of cognitive decline and risk 
of AD.
Method
PubMed and Scopus databases were searched, using 
“omega-3 fatty acids”, “Alzheimer’s disease” and “cogni-
tion” as key search terms, as well as variants of these (“n-3 
 European Journal of Nutrition
1 3
fatty acids, “PUFAs”, “AD”). Inclusion criteria were: (i) 
original randomised controlled trials (RCTs) or observa-
tional studies; of (ii) human participants ≥ 50 years; (iii) 
investigating the association between dietary or supple-
mented ω3 PUFAs; on (iv) qualitative or biological assess-
ment of cognitive function; (v) as a marker of AD risk. 
Exclusion criteria were: (i) in vitro or (ii) preclinical stud-
ies, and (iii) non-original or (iv) non-peer-reviewed publica-
tions. No exclusion regarding initial publication date was set 
and all studies published up to March 2020 were eligible. 
Identified studies were then compiled into tables to assess 
and compare the participant sample profile, methods, and 
outcomes in a clear and concise manner (see Tables 1, 2). 
Results
Eight observational studies and 25 RCTs were selected for 
review (see Supplementary Fig. 1).
Observational studies
The data from observational studies generally support an 
inverse association between dietary LC ω3 PUFA intake and 
cognitive decline and risk of AD (Table 1). The Rotterdam 
Study (1997) is the earliest account in this review of the link 
being demonstrated in a population-based cohort of elderly 
subjects (≥ 55 years). Data from this study showed a rela-
tive risk (RR) of AD at 0.3 (95% CI: 0.1–0.9) with daily fish 
consumption above 18.5 g [46]. Interestingly, a follow-up 
study in 2009 reported contrasting results [47]. Fish, total 
ω3, EPA and DHA intake of 5395 subjects did not associate 
with AD [47]. The 10-year follow-up period may have meant 
that baseline dietary information was not representative of 
the participants’ diets throughout the duration of the study; 
however, this does not rule out the potential relevance of 
earlier dietary habits in AD development.
Further studies have reported similar results [48–51], 
including a smaller cohort used in the Chicago Memory 
and Aging Project (n 815), wherein consumption of one or 
more fish meals per week generated a RR of 0.4 (95% CI: 
0.2–0.9), adjusted for age, sex, race, education, energy intake 
and presence of the ApoE ɛ4 polymorphism [49]. Although 
this result was near borderline significance (p = 0.07), the 
inverse, linear association between total ω3 PUFA intake 
and AD showed clear significance (p = 0.01) [49]. This 
relationship was also seen for DHA intake specifically, with 
those in the top three quintiles of intake showing multivar-
iate-adjusted RR as low as 0.2 (95% CI: 0.1–0.8) [49]. As 
less than 1% of the cohort reported taking ω3 PUFA sup-
plements, it can be deduced that this intake was primarily 
achieved through diet.
A later prospective study by Schaefer et al.[51] analysed 
baseline plasma DHA in participants of the Framingham 
Heart Study and found that those in the upper quartile (mean 
3 servings of fish/week) had an all-cause dementia RR of 
0.53 (95% CI: 0.29–0.97) compared to those in the lower 
three quartiles. Although of similar magnitude, the asso-
ciation between plasma DHA and AD was not significant 
(RR = 0.61; 95% CI: 0.31–1.18; p= 0.14) when upper and 
lower quartiles were compared [51]. The dietary intake 
of DHA was also high for these subjects in the cohort, at 
1800 mg/day. Fish intake was significantly associated with 
plasma DHA; however, once adjusted for plasma DHA, the 
association between dietary fish and DHA intake and AD 
was not significant [51]. This suggests that DHA is the pri-
mary component of fish effecting AD risk and underlines 
the importance of DHA bioavailability and absorption into 
the blood, which can be improved by co-ingestion of a high 
fat meal alongside supplement use [52]. In addition, vari-
ability of fish DHA content (% fatty acids) between spe-
cies and global region [53, 54], is likely to contribute to the 
heterogeneity of results we observed between observational 
studies and suggests that subgrouping fish intake by its DHA 
content may help to reduce this heterogeneity.
A more recent community-based cohort study, the Rush 
Memory and Aging Project, identified a decreased risk of 
AD in participants with the highest adherence scores to 
MIND (Mediterranean-DASH Intervention for Neurodegen-
erative Delay), DASH (Dietary Approaches to Stop Hyper-
tension) and Mediterranean diets, with hazard ratios (HR) 
at 0.47 (95% CI: 0.26–0.76), 0.61 (95% CI: 0.38–0.97) and 
0.46 (95% CI: 0.26–0.79), respectively [55]. In particular, 
the MIND diet showed a HR of 0.65 (95% CI: 0.44–0.98) 
even with moderate adherence [55]. In addition to ade-
quate intake of fish, the diet consists of 15 ‘brain-healthy’ 
food aspects, including increased fruit and vegetables and 
reduced red meat and butter, which make it difficult to 
deduce the role of LC ω3 PUFAs in ameliorating AD risk 
from these results. These findings agree with previous work 
investigating the combined effects of multi-nutritional LC 
ω3 PUFAs-rich drinks [56] on cognitive function and AD 
risk and encourage future studies to identify novel LC ω3 
PUFA-nutrient interactions or nutritional patterns that might 
offer even greater protection against cognitive impairment 
and future AD risk.
The same cohort was tested for cognitive ability using a 
21-test battery to assess global cognition and five specified 
cognitive domains, including episodic memory and visuos-
patial ability [57]. Although ω3 PUFAs from food sources 
were not associated with cognition, ω3 supplementation 
was significantly associated with slower rates of decline in 
global cognition and episodic memory scores compared to 
non-consumers [57]. This suggests that an increased habitual 
intake of ω3 PUFAs reliably delivers an adequate dosage to 
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Table 1  Observational studies investigating the association between dietary ω3 intake and AD risk
FFQ food frequency questionnaire
References Cohort Year Study characteristics Follow-up Dietary recall Findings
[46] Rotterdam Study 1997 n 5386
Age: ≥ 55 years
1.2 years Semi-quantitative FFQ Fish consumption 
(> 18.5 g/d) associated with 
a 70% reduced risk of AD 
without cerebrovascular 
disease (95% CI: 0.1–0.9)
[47] 2009 n 5395
Age: ≥ 55 years
9.6 years Total fish and ω3 PUFA 
intake not associated with 
long-term AD risk




5.4 years FFQ Consumption of fatty fish 
showed 41% decreased risk 
of AD in those without 
ApoE ɛ4 allele (95% CI: 
0.36–0.95)




3.9 years FFQ Consumption of one or more 
fish meal per week reduced 
risk of AD by 60% (95% 
CI: 0.2–0.9). Total ω3 
PUFA and DHA intake 
significantly and linearly 
associated with a reduced 
risk of AD
[50] Hordland Health Study 2007 n 2031
Age: 70–74 years
Cross-sectional FFQ Consumption of lean and 
fatty fish associated with 
better scores on five of six 
cognitive tests compared 
to no consumption. Fish 
oils only associated with 
improved scores in one of 
six tests
[51] Framingham Heart Study 2006 n 899
Age: 55–88 years
9.1 years Semi-quantitative FFQ Significant 47% reduc-
tion in risk of developing 
all-cause dementia in 
upper quartile of plasma 
DHA content (mean DHA 
intake = 0.18 g/d, mean fish 
intake = 3 servings/week) 
(95% CI: 0.29–0.97). No 
significant reduction in risk 
of AD specifically




4.5 years Semi-quantitative FFQ Moderate and high adherence 
to MIND diet showed lower 
risk of AD compared to first 
tertile. High adherence to 
DASH and Mediterranean 
diet also associated with 
lower AD risk
[57] 2016 n 915
Mean age: 81.4 years
4.9 years Intake of food sources of ω3 
PUFAs not associated with 
cognitive decline, however, 
fish oil supplement consum-
ers had slower rates of 
decline in global cognition 
and episodic memory meas-
ures than non-consumers
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influence cognitive outcomes. Several of these studies also 
identified a significant relationship between increased ALA 
consumption and reduced AD risk, but interestingly only in 
ApoE ɛ4 carriers [49, 57].
In summary, observational studies support the notion 
that LC ω3 PUFAs offer a protective effect against cognitive 
decline and risk of AD. The period of study in observational 
studies is far longer than can be realistically achieved in a 
clinical setting, meaning that prolonged exposure to dietary 
LC ω3 PUFAs can be represented in analysis, in comparison 
to a transient response to increased LC ω3 PUFA intake. 
However, the observational studies identified in this review 
were conducted on European and American populations, 
meaning that these data may not be generalisable to other 
populations with varying ratios of ApoE polymorphism, and 
differing quantities and sources of fish and LC ω3 PUFA 
consumption.
Future epidemiological studies are required to evaluate 
the distinct and interactive associations between LC ω3 
PUFAs and foods they are commonly consumed alongside 
(i.e., as in a Mediterranean diet) and the effect of cooking 
methods on the efficacy of LC ω3 PUFAs. Concurrent die-
tary parameters such as increased fruit and vegetable intake 
and decreased saturated fat intake may also play a role in 




The OmegAD trial [58] was the first large, randomised pla-
cebo-controlled trial to investigate the effects of ω3 PUFAs 
on the cognitive ability of AD patients (Table 2). Subjects 
were randomised to receive either ω3 PUFA capsules 
(1700 mg/day DHA and 600 mg/day) for the full 12 months 
of the study, or 6 months of placebo capsules followed by 
6 months of ω3 PUFA capsules. Scores for the Mini-Mental 
State Examination (MMSE) and the cognitive portion of the 
Alzheimer’s Disease Assessment Scale (ADAS-cog) were 
taken at baseline, 6 and 12 months; however, no statistically 
significant differences in scores between the two groups 
were established [58]. A subgroup of 32 patients with very 
mild AD (MMSE > 27 points) showed a significant attenua-
tion of cognitive decline compared to placebo, as indicated 
by MMSE score after 6 months of intervention [58].
A further study as part of the OmegAD trial found that 
the diminution of cognitive decline as measured by ADAS-
cog scores was significantly associated with increasing 
plasma DHA, and that plasma EPA was associated with a 
number of parameters within the ADAS-cog [59]. Similar 
conclusions can be drawn from a shorter trial by Chiu et al. 
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EPA content than the OmegAD trial (DHA:EPA 2:3 [60] vs 
3:1 [58]). Although the mixed model indicated a positive 
change in global clinical function in the intervention group, 
as measured by Clinician's Interview-Based Impression 
of Change (CIBIC), the improvement of ADAS-cog score 
over the intervention was selective to those with mild cogni-
tive impairment (MCI); no effect was seen in AD patients. 
Intriguingly, this study reported lower levels of plasma ARA 
in the ω3-treated group compared to the control [60], which 
may suggest a decrease in pro-inflammatory eicosanoid 
synthesis caused by the inhibitory action of EPA on ARA 
metabolism. Increased EPA on erythrocyte membranes was 
associated with improved ADAS-cog scores [60].
Zhang et al. [28] investigated the effect of high dose 
algal-derived DHA on cognitive function of those with 
MCI, defined as subjective memory complaints accompa-
nying a score of 1.5 standard deviations below age- and 
education-matched controls in MMSE memory subtest, but 
without the presence of AD or related diseases [28]. Fol-
lowing 12 months of supplementation with 2000 mg DHA/
day, the intervention group achieved significantly higher test 
scores for Full Scale Intelligence Quotient and subdomains 
of Information and Digit Span [28]. In a follow-up paper 
after 24 months of supplementation, the authors reported the 
same significant improvements as seen after 12 months, with 
an additional improvement in Verbal Intelligence Quotient 
[61]. This dosage has also been trialled in patients with mild 
to moderate AD (MMSE 14–26), but there was no significant 
effect on rate of cognitive decline as indicated by ADAS-cog 
and Clinical Dementia Rating (CDR) [27]. It may be impor-
tant to note that one of the placebos used in these studies was 
soybean oil, known to contain, amongst other fatty acids, a 
significant amount of ALA [13], which may have compro-
mised the estimate of the effect size. Indeed, as a precursor 
for LC ω3 PUFA, it is likely that a small percentage of ALA 
was synthesised into EPA or DHA and contaminated the 
control group; however, without another control group, the 
magnitude of contamination cannot be determined.
The efficacy of LC ω3 PUFA supplementation on MCI 
has been further investigated by a number of trials [62–65]. 
Yurko-Mauro et al. [62] examined DHA supplementation in 
subjects with age-related cognitive decline (MMSE > 26). 
After 24 weeks of treatment (900 mg/day), the intervention 
group had significantly fewer Paired Associate Learning pat-
tern errors than placebo subjects, as well as improved imme-
diate and delayed Verbal Recognition Memory [62]. These 
changes were significantly associated with increased plasma 
DHA levels, of which the intervention group exhibited a 
twofold rise in plasma DHA [62]. Improved immediate ver-
bal memory has also been reported in MCI patients treated 
with DHA-EPA combination supplements [63] and DHA 
supplements at a substantially lower dosage [64]. Interest-
ingly, this study [64] delivered 240 mg/day DHA alongside 
an equivalent dose of ARA. Increased concentration of 
ARA in neuronal membranes may have increased the fluid-
ity index of brain cells in the treated group, consequently 
leading to improved synaptic function. By contrast, AD sub-
jects did not exhibit any improvement in immediate memory 
[64]. Similar findings were documented in another trial [65]; 
however, this study also found no association between LC 
ω3 PUFA supplementation (625 mg/day DHA 600 mg/day 
EPA) and cognitive function in cognitively impaired indi-
viduals without dementia (CIND), contradicting evidence 
from other research [62–64]. These studies raise questions 
regarding the effects of study parameters, such as study dura-
tion and dosage, that may have contributed to the results of 
trials successfully associating LC ω3 PUFAs with improved 
cognition in MCI. Specifically, they suggest that durations 
of ≥ 5 months and DHA supplements exceeding 900 mg/day, 
are required to elicit a significant effect on cognitive ability 
in elderly populations.
Several large-scale trials (n ~ 1600–3400), including 
the Multidomain Alzheimer Preventive Trial (MAPT) and 
Alpha Omega Trial, have found no association between LC 
ω3 PUFAs and cognition, both in those with memory com-
plaints [66, 67] and those deemed cognitively healthy [68, 
69]. Although these studies use large sample sizes and sub-
stantial intervention periods, the dosage of LC ω3 PUFAs 
are comparatively lower than in other trials conducted in this 
area (Table 2). While these levels better mimic the level of 
ω3 PUFAs achievable through the diet, the results of studies 
using higher supplementary doses have more consistently 
reported significant effects of LC ω3 PUFAs on cognitive 
function in MCI [28, 61, 63] and at-risk older individuals 
[70]. Interestingly, a secondary analysis of MAPT study sub-
jects with memory complaints in the lowest quartile of ω3 
index revealed an increase in Controlled Oral Word Associa-
tion Test (COWAT) scores for the intervention group over 
the 36-month intervention, where the control group experi-
enced a decrease in mean score [71]. Although this was the 
only finding to achieve statistical significance, the interven-
tion group performed better than the placebo group in all 
other tests conducted [71]. Interestingly, a smaller 6-month 
trial (n 199) supports these findings in cases of MCI, report-
ing no significant change in MMSE or Abbreviated Mental 
Test (AMT) following ω3 PUFA supplementation [72].
Scheltens et al. [73] randomised patients with mild AD 
(MMSE 20–26) to receive either 1200 mg/day DHA and 
300 mg/day EPA as a medical supplement drink (Souve-
naid), or an isocaloric placebo drink, for 12 weeks. A signifi-
cant improvement was reported in revised Wechsler Memory 
Scale (WMS-R) delayed recall score, although ADAS-cog 
and CIBIC scores did not change. A subgroup analysis 
of patients with very mild AD also achieved significantly 
improved immediate verbal recall after 12 weeks [73]. A 
24-month trial on a similar population with prodromal AD 
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(mean age 71, mean MMSE 26.7) has since been conducted 
to establish the longer term influence of Souvenaid [74]. 
The authors reported a moderately positive effect based on 
lower rates of cognitive decline in the intervention group 
than were expected based on projected 24-month decline 
observed in AD patients [75]. However, no significant effect 
on the composite score of the neuropsychological test bat-
tery used was reported [74]. Souvenaid contains a combi-
nation of other nutrients including vitamin C (80 mg) and 
a number of B-vitamins (3 μg B12, 1 mg B6, 400 μg folic 
acid). Interactions between B-vitamins and ω3 PUFAs in 
affecting reduced rates of brain atrophy have been reported 
in MCI [76]. Although the efficacy of B-vitamin treatment in 
AD is still yet to be thoroughly established [77], the poten-
tial for the effects observed in the Souvenaid trials to be 
influenced by the additional nutrients in the drink make it 
difficult to isolate the impact of ω3 PUFAs alone.
The Souvenaid trials raised questions about the combi-
nation of ω3 PUFAs with other agents in supplementation. 
Shinto et al.[78] analysed the effects of ω3 PUFA treatment 
(675 mg/day DHA 975 mg/day EPA) with and without the 
addition of α-lipoic acid (600 mg/day), an organosulphur 
compound and antioxidant implicated in the protection of 
mitochondria from oxidative damage [79] and reduction 
of inflammatory markers [78], as is seen in AD. Although 
no significant difference was found in ADAS-cog scores, 
Instrumental Activities of Daily Living (IADL) scores of 
probable AD subjects showed significantly less decline over 
the 12-month trial period for both ω3 and ω3-α-lipoic acid 
groups compared to placebo; however, a significant dif-
ference between MMSE scores for treatment and placebo 
groups was only observed in the case of combined ω3-α-
lipoic acid supplementation [78]. As levels of endogenous 
α-lipoic acid decrease with age [79], these results suggest 
the use of lipoic acid in conjunction with ω3 PUFA sup-
plementation may have biological plausibility for cases of 
late-onset AD, although further research is warranted. In the 
placebo arm, the authors used a capsule containing soybean 
oil and 5% fish oil [78]. While the ω3 concentrations may not 
have been as high as in the intervention arm, the potential 
influence on results is worth noting.
Biomarkers
As well as cognitive testing, numerous studies also meas-
ured biological changes as indicators of cognitive function 
[78, 80–84]. As part of the OmegAD study, 35 AD sub-
jects were randomised to 6-month supplementation of ω3 
PUFAs (1700 mg/day DHA 600 mg/day EPA) or placebo 
[80]. Plasma samples were tested at baseline and 6 months 
for the inflammatory markers IL-6, tumour necrosis factor-
alpha (TNF-α) and soluble interleukin-1 receptor type-II 
(sIL-1RII). Cerebrospinal fluid was extracted by lumbar 
puncture at baseline and 6 months and tested for IL-6, TNF-
α, sIL-1RII, as well as tau protein, hyperphosphorylated tau 
protein and Aβ peptides, all hallmarks of AD pathology [33]. 
A significant association between sIL-1RII and Aβ42 was 
made at baseline; however, no associations related to ω3 
PUFAs were found with any of the biomarkers measured 
[80]. The same sample was examined for changes in uri-
nary F2-isoprostanes and prostaglandin  F2α, both formed 
through COX pathways associated with oxidative stress [81]. 
15-keto-dihydro-PGF2α, a metabolite of prostaglandin  F2α, 
was used as a biomarker of inflammation. No changes were 
observed in any of these biomarkers. Further research on ω3 
PUFA supplementation and F2-isoprostane levels in cases 
of probable AD reached a similar conclusion [78]. However, 
neither study reported a qualitative assessment of cogni-
tive function at baseline and follow-up, so it is not possible 
to confirm the null hypothesis or validate the association 
between biomarkers and cognitive function.
A number of biomarker studies have reported associa-
tions between ω3 PUFAs and quantitative indicators of cog-
nitive function [82, 83]. A cerebral perfusion study revealed 
increased cerebral blood flow and volume in posterior corti-
coid regions of MCI subjects following high dose ω3 PUFA 
supplementation (880 mg/day DHA and 1320 mg/day EPA) 
for 6 months [82]. Cerebral hypoperfusion has been associ-
ated with AD as a consequence of neuronal tissue damage 
and brain atrophy [85]. Although no statistically significant 
effect of 18-month high dose DHA supplementation was 
reported in slowing the rate of brain atrophy in cases of 
mild to moderate AD [62], a more recent study [61] of simi-
lar design with a larger sample size (n 219 vs 102 [62]) 
identified an association between the same DHA dosage 
(2000 mg/day) and increased hippocampal volume in MCI 
subjects after 12 months [61]. In another study, administra-
tion of a drink containing 1000 mg DHA and 1000 mg EPA 
amongst other nutrients, including vitamin D and resveratrol 
(Smartfish), was significantly associated with increased Aβ 
phagocytosis by monocytes as indicated by flow cytometry 
in MCI and pre-MCI subjects, but not in AD [83]. These 
studies further support the efficacy of LC ω3 PUFAs as 
early interventions and suggest that physical brain measures, 
while time-consuming and costly, provide a more reliable 
measure of cognitive degeneration compared to blood and 
cerebrospinal fluid analytes.
The largest biomarker study identified in this review, with 
more than 100 subjects, was undertaken by Faxén-Irving 
and colleagues, as a further part of the OmegAD trial [84]. 
Transthyretin, a Aβ binding protein thought to reduce plaque 
formation [86], was the compound of interest. 174 patients 
with mild to moderate AD completed two consecutive 
6-month supplementation periods as two groups—ω3/ω3 
and placebo/ω3. Plasma transthyretin levels after 6 months 
significantly decreased in the placebo group, at which point 
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a correlation was identified between DHA and transthyretin 
(rho = 0.17, p = 0.03) [84]. At the 12-month follow-up, after 
both groups had been supplemented with ω3 PUFAs, plasma 
transthyretin increased significantly in both groups, at which 
point a correlation was identified between MMSE scores 
and transthyretin (rho = 0.16, p = 0.03), alongside an inverse 
correlation with ADAS-cog scores (rho = − 0.2, p = 0.02) 
[84]. Cerebrospinal fluid was analysed over 6 months in a 
subset of 35 subjects; however, the increase in cerebrospinal 
fluid transthyretin observed in the ω3/ω3 treatment group 
was not significant [84]. This trial is one of few that offers 
evidence that ω3 PUFAs may improve cognition in those 
with established AD.
In controlled trials, participants have usually already 
received a diagnosis of AD, meaning that ω3 PUFAs are 
tested for their treatment effect on a disease that has already 
been established with notably manifested symptoms of 
memory impairment. Indeed, based on the data reviewed 
here, wherein the majority of clinical trials that made posi-
tive associations between supplementation and cognition 
were conducted in cases of MCI as opposed to AD, a pro-
tective effect of ω3 PUFAs is inferred.
Conclusion
Cognitive impairment and AD present major challenges for 
clinical medicine, with multi-faceted pathologies that are 
still not entirely understood. The role of environmental fac-
tors to prevent cognitive impairment and subsequent AD 
continues to be an area of extensive research, particularly 
pertinent to late-onset cases. Due to their widely recog-
nised influence on cognitive function, ω3 PUFAs present a 
compelling opportunity for nutritional therapy in cognitive 
decline and AD.
Evidence from observational studies appears promising 
for prevention of cognitive decline. Regular consumption of 
LC ω3-PUFA rich foods in healthy populations without pre-
existing AD or dementia suggests a protective effect against 
future AD. Conversely, clinical trials that primarily focus on 
participants already diagnosed with AD consistently report 
no effect. The incongruence between these findings high-
lights the precedence of LC ω3 PUFA intake earlier in life, 
before cognitive decline is apparent and AD risk has been 
recognised.
Although many observational studies adjusted for known 
confounders, including the ApoE ɛ4 allele, this was not con-
sistent across the literature. Those that specifically analysed 
ApoE ɛ4 suggest that the metabolic effects of different LC 
ω3 PUFAs differ between ɛ4 carriers and non-carriers; there-
fore, more targeted studies within this high-risk population 
are warranted to better understand ɛ4-specific effects of dif-
ferent types of LC ω3 PUFAs.
Overall, LC ω3 PUFA supplementation appears to be 
well-tolerated, even in high doses (Table 2). Although 
LC ω3 PUFAs may not be a validated treatment strategy 
for cognitive impairment or AD based on the current evi-
dence, their successful implementation as an early inter-
vention strategy for neuroprotection in MCI and healthy 
older populations is encouraging. Large-scale trials of 
long duration (≥ 5 months) using higher dosage supple-
ments (900 mg DHA/day) across diverse populations are 
required to validate these findings, to improve general-
isability and determine safe and optimum dosage. Fur-
thermore, the combination of LC ω3 PUFAs with other 
nutrients of interest, such as α-lipoic acid and B-vitamins, 
is an intriguing area of research that may identify addi-
tional supplementation strategies and nutrient interactions 
to prevent and ameliorate cognitive decline in the elderly.
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